Here are Friday's biggest analyst calls: Nvidia, Apple, Tesla, Netflix, Disney, Alphabet, Tripadvisor & more

About two dozen analyst actions were reported, skewing positive with multiple upgrades and initiations across sectors. Notable calls include BMO initiating Honeywell as outperform, B. Riley initiating FuboTV with a $18 12-month target, UBS upgrading Wheaton Precious Metals to Buy with a $160 target, Canaccord initiating NovaGold at a $13 target, and Nomura upgrading PDD with a $136 TP; Wells lowered Disney's PT to $148 from $150 and raised Alphabet's PT to $397. The activity signals broad analyst optimism for select tech, biotech, energy and materials names and is likely to move individual stocks rather than the broader market.

Analysis

The wave of upgrades clusters into three coherent narratives: AI/compute, industrial/capex recovery, and idiosyncratic re-rates (spins/activism). That clustering creates concentrated flow into a small set of liquid names (NVDA, GOOGL, AAPL) which will amplify moves on earnings or guidance revisions and compress bid-ask liquidity in midsize beneficiaries (PWR, PRMB, WPM), raising the chance of abrupt, outsized re-rating on positive headlines.

AI exposure remains the highest-conviction macro driver but is increasingly priced; the marginal buyer is now funding expected software monetization (FSD, Gemini) rather than raw GPU cycles. That shifts the risk window from quarters (capex cycles) to years (software TAM capture): catalysts that under- or over-deliver on monetization (e.g., large enterprise FSD/internal AI deals) will move multiples far more than incremental data-center bookings.

Infrastructure and energy-linked names (PWR, CHRD, SPXC) are entering a period where government or utility procurement timelines matter more than commodity moves — a single major transmission award or a solar+storage completion can drive multiquarter upside. Conversely, precious-metals and exploration names (WPM, NG) are sensitive to real-rate trajectories and permitting/geopolitics that can swing valuations >30% in months.

Biotech/psychedelic initiations (ATAI, BIOA) are classic binary stories: headlines and phase transitions will dominate near-term returns; these are allocative, not conviction, trades. Use tight sizing and option structures to control event risk while leaning into long-duration, idiosyncratic industrial compounders (LASR, PRMB) where secular defense/HVAC budgets provide multi-year tailwinds.

Key Decisions for Investors

• Long NVDA LEAPs (buy Jan-2027 ATM call or 1:1 550/800 call spread depending on cost): 9–15 month horizon. Rationale: continued AI software monetization optionality plus multiple expansion; target +50–100% pay-off if enterprise AI/GPU demand remains strong. Position size: 2–4% NAV; max loss = premium. Trim into 40–60% gains, stop-loss at 40% premium decay.
• Pair trade — long Quanta Services (PWR) / short XLI equal notional: 6–12 month horizon. Rationale: discrete transmission & T&D awards plus inorganic EBITDA optionality should outpace broader industrials. Target relative outperformance of 30–50%; absolute stop-loss: 12% on the long leg, rebalance if sector breadth improves.
• Event-driven long HON ahead of spin updates: buy shares or buy-to-open Dec-2026 1–2x covered calls with a protective put (10–12% delta) as hedge. Horizon 6–12 months to capture re-rate on clearer asset separation and potential buybacks; target 15–30% upside net of hedge, risk limited by downside protection. Size 3–5% NAV.
• Tactical short / option hedge on psychedelic/early-stage biotech basket (ATAI, BIOA): buy 3–6 month puts or buy OTM long-dated puts as volatility hedge. These are binary, headline-driven names — cap exposure at 1–2% NAV total. Aim to capture 2–5x payoff on negative trial/regulatory surprises while preserving capital if positive catalysts occur.